Q3 2024 Earnings Call Transcript November 4, 2024 Medifast, Inc. beats earnings expectations. Reported EPS is $0.1029, ...

Despite a significant revenue drop, Medifast Inc (MED) focuses on innovation and strategic marketing to counteract market pressures and competition.

The weight loss segment of the health and wellness ... a decrease of 36.3% from the third quarter of 2023. Average revenue per active earning OPTAVIA Coach for the second quarter was $4,672 ...

Real-time index price for TSX 60 Equal Weight Index (TXEW), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

“Medical innovation has transformed the weight loss industry, so at Medifast we ... Chairman & CEO. Known for its Optavia program that combines portion-controlled meal replacements with ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

Losing weight on GLP-1 drugs like Ozempic isn't guaranteed. Experts reveal how to tell if yours isn't working and the next steps you should take to reach your weight loss goals.

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...